Lite Strategy, Inc. (LITS)
1.03
+0.06
(+5.96%)
USD |
NASDAQ |
Nov 06, 10:25
Lite Strategy Net Income (Quarterly) : -13.02M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -13.02M |
| March 31, 2026 | -23.69M |
| December 31, 2025 | -30.80M |
| September 30, 2025 | -3.639M |
| June 30, 2025 | -2.688M |
| March 31, 2025 | -2.573M |
| December 31, 2024 | -2.677M |
| September 30, 2024 | -8.007M |
| June 30, 2024 | -18.41M |
| March 31, 2024 | -9.127M |
| December 31, 2023 | -11.06M |
| September 30, 2023 | 56.37M |
| June 30, 2023 | -10.03M |
| March 31, 2023 | -15.44M |
| December 31, 2022 | 10.25M |
| September 30, 2022 | -16.62M |
| June 30, 2022 | -16.06M |
| March 31, 2022 | -8.725M |
| December 31, 2021 | -12.16M |
| September 30, 2021 | -17.51M |
| June 30, 2021 | -8.378M |
| March 31, 2021 | -25.62M |
| December 31, 2020 | -8.026M |
| September 30, 2020 | -2.092M |
| June 30, 2020 | -18.48M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.329M |
| December 31, 2019 | -20.22M |
| September 30, 2019 | -2.994M |
| June 30, 2019 | 3.053M |
| March 31, 2019 | -17.36M |
| December 31, 2018 | 12.02M |
| September 30, 2018 | -14.54M |
| June 30, 2018 | -19.25M |
| March 31, 2018 | -5.948M |
| December 31, 2017 | -6.079M |
| September 30, 2017 | -8.788M |
| June 30, 2017 | -4.343M |
| March 31, 2017 | -0.602M |
| December 31, 2016 | 11.88M |
| September 30, 2016 | -4.27M |
| June 30, 2016 | -5.77M |
| March 31, 2016 | -5.371M |
| December 31, 2015 | -5.101M |
| September 30, 2015 | -4.62M |
| June 30, 2015 | -5.662M |
| March 31, 2015 | -8.93M |
| December 31, 2014 | -9.109M |
| September 30, 2014 | -8.993M |
| June 30, 2014 | -8.541M |
| March 31, 2014 | -7.387M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | -9.605M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 13.02M |
| EPS Diluted (Quarterly) | -0.3761 |
| Enterprise Value | 25.80M |
| Earnings Yield | -192.9% |
| Normalized Earnings Yield | -81.41 |